Facebook Instagram X-twitter Linkedin

FOXO4 (10mg)

Table of Contents

  • Quickstart Highlights

FOXO4 (10mg) protocols focus on this investigational peptide designed to selectively target senescent (aged or damaged) cells by disrupting the FOXO4–p53 interaction. By promoting apoptosis of these dysfunctional cells, FOXO4 may support cellular rejuvenation, tissue health, and improved biological function. This guide outlines a subcutaneous administration approach optimized for the 10 mg vial format.

  • Reconstitute: Add 2.0 mL bacteriostatic water → 5 mg/mL concentration
  • Typical range: 2–5 mg per dose (subcutaneous, intermittent use)
  • Easy measuring: At 5 mg/mL, 1 unit = 0.01 mL = 50 mcg (0.05 mg) on a U-100 insulin syringe
  • Storage: Lyophilized: store at −20 °C; after reconstitution, refrigerate at 2–8 °C and use within 2–4 weeks
  • Protocol Overview

Concise summary of the subcutaneous regimen.

  • Goal: Support removal of senescent cells and promote cellular health
  • Schedule: Intermittent dosing (not daily); commonly used in short cycles
  • Dose Range: 2–5 mg per administration
  • Cycle Approach: Periodic use (e.g., a few doses per cycle followed by extended breaks)
  • Dosing Protocol

Suggested approach for the 10 mg vial format.

  • Start: 2 mg per dose to assess tolerance
  • Target: 3–5 mg per dose
  • Frequency: Intermittent (e.g., 1–3 times per week during a cycle)
  • Vial Duration: One 10 mg vial typically provides 2–5 doses
  • Timing: Flexible; spacing doses evenly is recommended
  • Mechanism of Action

FOXO4-based peptides (such as FOXO4-DRI) are designed to disrupt the interaction between FOXO4 and p53 within senescent cells. In these cells, FOXO4 helps retain p53 in the nucleus, preventing apoptosis.

By interfering with this interaction, FOXO4 peptides allow p53 to trigger programmed cell death specifically in senescent cells. The removal of these cells may reduce inflammatory signaling (often referred to as the senescence-associated secretory phenotype, or SASP) and improve tissue function. Preclinical studies have shown potential benefits in aging-related dysfunction and tissue regeneration.

  • Potential Benefits & Side Effects

Observations based on preclinical and early-stage research.

Potential Benefits:

  • May help clear senescent (aging/damaged) cells
  • May support tissue regeneration and cellular health
  • Potential reduction in chronic inflammation linked to aging
  • May improve physical function in preclinical models

Possible Side Effects:

  • Fatigue or temporary discomfort post-dose
  • Injection-site irritation
  • Limited human data; effects largely based on animal studies
  • Long-term safety not established; remains investigational